The quality of reporting of randomized controlled trials in solid organ transplantation

Transplant International

Volumn 22, Issue 4, 2009, Pages 377-384

  Pengel, Liset H M ^b   Barcena, Leticia ^b   Morris, Peter J ^a,b  

^a ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Methodological quality; Randomized controlled trials; Solid organ transplantation

Indexed keywords

HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MEDICAL LITERATURE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

HUMANS; MULTICENTER STUDIES AS TOPIC; ORGAN TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 61849135251     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00789.x     Document Type: Review

References (18)

1. Pildal J, Chan AW, Hrobjartsson A, Forfang E, Altman DG, Gotzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ 2005 330 : 1049.
2. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, Gotzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol 2007 36 : 847.
3. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001 135 : 982.
4. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998 352 : 609.
5. Kane RL, Wang J, Garrard J. Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J Clin Epidemiol 2007 60 : 241.
6. Barcena L, Pengel L, Morris PJ. Registry of randomized controlled trials in transplantation. Transplantation 2005 80 : 1525.
7. Morris PJ. Quality of randomized trials in solid organ transplantation. Transplantation 2005 80 : 431.
8. Juni P, Altman DG, Egger M. Assessing the quality of randomised controlled trials. In : Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-Analysis in Context. London : BMJ Publishing Group, 2001 : 87.
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 : 1.
10. Balasubramanian SP, Wiener M, Alshameeri Z, Tiruvoipati R, Elbourne D, Reed MW. Standards of reporting of randomized controlled trials in general surgery: can we do better? Ann Surg 2006 244 : 663.
11. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 2002 31 : 115.
12. Hopewell S, Altman DG, Moher D, Schulz KF. Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors'. Trials 2008 9 : 20.
13. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003 326 : 1167.
14. Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Serv Res 2002 2 : 18.
15. Morris PJ, Ploeg RJ. Help in the design and reporting of randomized controlled trials: a collaboration between ESOT and CET towards a knowledge centre for European transplantations. Transpl Int 2008 21 : 511.
16. Barcena L, Pengel L, Morris PJ. Searching the transplantation library. Transplantation 2008 85 : 1068.
17. Netto GJ, Watkins DL, Williams JW, et al. Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multi-institutional trial experience. Arch Pathol Lab Med 2006 130 : 1157.
18. Wabbijn M, Balk AH, van Domburg RT, et al. Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor. Exp Clin Transplant 2004 2 : 201.